Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

Next Previous
Search
Trial Profile

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ACALLO

    • Most Recent Events

    • 16 Jan 2025 Status changed from active, no longer recruiting to completed.
    • 11 Apr 2024 Planned End Date changed from 31 Jul 2024 to 30 Sep 2024.
    • 11 Apr 2024 Planned primary completion date changed from 31 Mar 2024 to 30 Jun 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top